Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Accumulated Expenses (2018 - 2025)

Addex Therapeutics' Accumulated Expenses history spans 8 years, with the latest figure at $681375.8 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 15.04% to $681375.8 in Q4 2025 year-over-year; TTM through Dec 2025 was $681375.8, a 15.04% increase, with the full-year FY2025 number at $656846.7, up 10.9% from a year prior.
  • Accumulated Expenses came in at $681375.8 for Q4 2025, down from $860.6 billion in the prior quarter.
  • The five-year high for Accumulated Expenses was $860.6 billion in Q3 2025, with the low at $592276.3 in Q4 2024.
  • Historically, Accumulated Expenses has averaged $143.4 billion across 5 years, with a median of $1.5 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: surged 36.19% in 2021 and later crashed 57.47% in 2024.
  • Year by year, Accumulated Expenses stood at $2.0 million in 2021, then dropped by 17.59% to $1.7 million in 2022, then dropped by 16.07% to $1.4 million in 2023, then tumbled by 57.47% to $592276.3 in 2024, then rose by 15.04% to $681375.8 in 2025.
  • Business Quant data shows Accumulated Expenses for ADXN at $681375.8 in Q4 2025, $860.6 billion in Q3 2025, and $592276.3 in Q4 2024.